Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC

NCT04543110 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer

Interventions

DRUG: Durvalumab
RADIATION: Immune Modulating Radiation

Sponsor

Ottawa Hospital Research Institute

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]